LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
=== Protein tags === BCCP (Biotin Carboxyl Carrier Protein), a protein domain biotinylated by BirA enabling recognition by streptavidin BromoTag, a "bump-and-hole" mutated version of the second bromodomain of Brd4, Brd4-BD2 L387A, that can be highly selectively bound by tag-specific PROTAC degrader AGB1 to form a ternary complex between the "BromoTagged" protein and the E3 ligase VHL, leading to ubiquitination of the tagged protein and its subsequent rapid and effective proteasomal degradation in cells. FAST (Fluorescence-Activating and absorption-Shifting Tag), a mutated photoactive yellow protein (PYP) that reversibly binds cognate fluorogenic ligands CL7-tag, an engineered variant of Colicin E7 that has a strong binding affinity and specificity for immobilized Immunity Protein 7 (Im7). Glutathione-S-transferase-tag, a protein which binds to immobilized glutathione Green fluorescent protein-tag, a protein which is spontaneously fluorescent and can be bound by nanobodies HaloTag, a mutated bacterial haloalkane dehalogenase that covalently attaches to haloalkane substrates SNAP-tag, a mutated eukaryotic DNA methyltransferase that covalently attaches to benzylguanine derivatives CLIP-tag, a mutated eukaryotic DNA methyltransferase that covalently attaches to benzylcytosine derivatives HUH-tag, a sequence-specific single-stranded DNA binding protein that covalently binds to its target sequence Maltose binding protein-tag, a protein which binds to amylose agarose Nus-tag Thioredoxin-tag Fc-tag, derived from immunoglobulin Fc domain, allow dimerization and solubilization.
Double-knot toxin (DkTx), also known as Tau-theraphotoxin-Hs1a or Tau-TRTX-Hs1a, is a toxin found in the venom of the Chinese Bird spider (Ornithoctonus huwena or Cyriopagopus schmidti), a tarantula species primarily living in the Guangxi province of China. This toxin, characterized by its bivalent structure of two Inhibitor Cysteine Knots (ICK), is thought to induce excruciating and long-lasting pain by activating the transient receptor potential vanilloid 1 (TRPV1) channel.
== Legal basis == As early as 1905, the Frenchman Viktor Hennecart called for special legislation to regulate the use of X-rays. In England, Sidney Russ (1879-1963) suggested to the British Roentgen Society in 1915 that it should develop its own set of safety standards, which it did in July 1921 with the formation of the British X-Ray and Radium Protection Committee. In the United States, the American X-Ray Society developed its own guidelines in 1922. In the German Reich, a special committee of the German X-Ray Society under Franz Maximilian Groedel (1881-1951), Hans Liniger (1863-1933) and Heinz Lossen (1893-1967) formulated the first guidelines after the First World War. In 1953, the employers' liability insurance associations issued the accident prevention regulation "Use of X-rays in medical facilities" based on the legal basis in § 848a of the Reich Insurance Code (RVG). In the GDR, the Occupational Safety and Health Regulation (ASAO) 950 was in effect from 1954 to 1971. It was replaced by ASAO 980 on April 1, 1971.
== Imaging Mass Cytometry (IMC) == Imaging mass cytometry (IMC) is a relatively new imaging technique, emerged from previously available CyTOF technology (cytometry by time of flight), that combines mass spectrometry with UV laser ablation to generate pseudo images of tissue samples. This approach adds spatial resolution to the data, which enables simultaneous analysis of multiple cell markers at subcellular resolution and their spatial distribution in tissue sections. The IMC approach, in the same way as CyTOF, relies on detection of metal-tagged antibodies using time-of-flight mass spectrometry, allowing for quantification of up to 40 markers simultaneously.
Sources: en.wikipedia.org
Kidnapping for extortion and political purposes Simple kidnapping According to data from the Directorate of Justice and Security of the DNP, this phenomenon shows an increasing trend. With respect to the costs of sequestration, the sources suggest an increasing behavior between 1996 and 2003, such that "the average annual growth rate is 9.3%, the highest rate is observed in 1998 (46.2%), and in 2000 (37.2%) year in which the number of kidnappings also it is significantly high [...] reaching its peak in the year 2000 with 1,938 cases." From then on, the trend decreases, except for a peak in 2002 with 1,542 cases, until reaching 350 kidnappings in 2005 (the lowest figure since 1996). Within these costs, 64.4% are direct, representing US$167.4 million. 35.6% of the remaining costs are indirect, and represent US$92.7 million. In 2004, the costs of sequestration were reduced to $109,519 million, representing 0.27% of GDP in 2003.
== External links == Lipoprotein(a) at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P08519 (Apolipoprotein(a)) at the PDBe-KB.
=== Techniques === Mass spectrometry of proteins requires that the proteins in solution or solid state be turned into an ionized form in the gas phase before they are injected and accelerated in an electric or magnetic field for analysis. The two primary methods for ionization of proteins are electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI). In electrospray, the ions are created from proteins in solution, and it allows fragile molecules to be ionized intact, sometimes preserving non-covalent interactions. In MALDI, the proteins are embedded within a matrix normally in a solid form, and ions are created by pulses of laser light. Electrospray produces more multiply-charged ions than MALDI, allowing for measurement of high mass protein and better fragmentation for identification, while MALDI is fast and less likely to be affected by contaminants, buffers and additives. Whole-protein mass analysis is primarily conducted using either time-of-flight (TOF) MS, or Fourier transform ion cyclotron resonance (FT-ICR). These two types of instrument are preferable here because of their wide mass range, and in the case of FT-ICR, its high mass accuracy. Electrospray ionization of a protein often results in generation of multiple charged species of 800 < m/z < 2000 and the resultant spectrum can be deconvoluted to determine the protein's average mass to within 50 ppm or better using TOF or ion-trap instruments.
=== Pharmacodynamics === NM-2-AI acts as a highly selective norepinephrine reuptake inhibitor and releasing agent in vitro and does not release serotonin or dopamine even at very high concentrations (100 μM). NM-2AI has high affinity (2.4 μM IC50) as a norepinephrine reuptake inhibitor but also has affinity as a TAAR1 receptor agonist (3.3 μM EC50), an Alpha-2A adrenergic receptor agonist (0.49 μM Ki) and as a binding agent at the 5-HT1A (3.6 μM Ki) and 5-HT2A (5.4 μM Ki) receptors.
=== Antiasthmatic medicines and medicines for chronic obstructive pulmonary disease === Budesonide Budesonide/formoterol (budesonide + formoterol) Epinephrine (adrenaline) Ipratropium bromide Salbutamol Tiotropium
Sources: en.wikipedia.org
==== Redox reactions ==== Redox reactions are prevalent for the transition elements. Two classes of redox reaction are considered: atom-transfer reactions, such as oxidative addition/reductive elimination, and electron-transfer. A fundamental redox reaction is "self-exchange", which involves the degenerate reaction between an oxidant and a reductant. For example, permanganate and its one-electron reduced relative manganate exchange one electron:
At the Battle of Carabobo on 24 June, the Gran Colombian forces decisively defeated the royalist forces, assuring control of Venezuela save for Puerto Cabello and guaranteeing Venezuelan independence. Bolívar could now concentrate on Gran Colombia's claims to southern New Granada and Quito.
Pakistan's desire for a united Islamic bloc, called Islamistan, wasn't supported by other Muslim governments, though figures like the Grand Mufti of Palestine, Al-Haj Amin al-Husseini, and leaders of the Muslim Brotherhood were drawn to the country. Pakistan's desire for an international organisation of Muslim countries was fulfilled in the 1970s when the Organisation of Islamic Conference (OIC) was formed. In East Pakistan, Bengali Muslims increasingly prioritised Bengali ethno-nationalism over religious nationalism. The Islamist party Jamaat-e-Islami backed an Islamic state and opposed Bengali nationalism. After the 1970 general elections, the Parliament crafted the 1973 Constitution. It declared Pakistan an Islamic Republic, with Islam as the state religion, and mandated laws to comply with Islamic teachings laid down in the Quran and Sunnah and that no law repugnant to such injunctions could be enacted. Additionally, it established institutions like the Shariat Court and the Council of Islamic Ideology to interpret and apply Islam. Zulfikar Ali Bhutto faced opposition under the banner of Nizam-e-Mustafa ("Rule of the Prophet"), advocating an Islamic state. Bhutto conceded to some Islamist demands before being ousted in a coup. General Zia-ul-Haq, after seizing power, committed to establishing an Islamic state and enforcing sharia law. He instituted Shariat judicial courts, and court benches, to adjudicate using Islamic doctrine. Zia aligned with Deobandi institutions, exacerbating sectarian tensions with anti-Shia policies.
Development of medication is a vital concern to medicine, but also has strong economical and political implications. To protect the consumer and prevent abuse, many governments regulate the manufacture, sale, and administration of medication. In the United States, the main body that regulates pharmaceuticals is the Food and Drug Administration; they enforce standards set by the United States Pharmacopoeia. In the European Union, the main body that regulates pharmaceuticals is the European Medicines Agency (EMA), and they enforce standards set by the European Pharmacopoeia. The metabolic stability and the reactivity of a library of candidate drug compounds have to be assessed for drug metabolism and toxicological studies. Many methods have been proposed for quantitative predictions in drug metabolism; one example of a recent computational method is SPORCalc. A slight alteration to the chemical structure of a medicinal compound could alter its medicinal properties, depending on how the alteration relates to the structure of the substrate or receptor site on which it acts: this is called the structural activity relationship (SAR). When a useful activity has been identified, chemists will make many similar compounds called analogues, to try to maximize the desired medicinal effect(s). This can take anywhere from a few years to a decade or more, and is very expensive. One must also determine how safe the medicine is to consume, its stability in the human body and the best form for delivery to the desired organ system, such as tablet or aerosol.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.